Intervention for Group 2
PreclinicalSmall molecule
Intervention for Group 2 is one of 53 small molecule programs targeting Liver Cancer. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
52
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
61 competitors in Liver Cancer
#DrugCompanyPhaseTrials
1Idamycin
PfizerApproved
Blenoxane
Bristol-Myers SquibbApproved
Taxol
TevaApproved
Opdivo
Bristol-Myers SquibbPhase 3
Baraclude
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Eloxatin
TevaPhase 3
Lenvima
EisaiPhase 3
Alimta
SShawn Eagle
Approved
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Rapamune
PPrism Pharmaceuticals
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Intervention for Group 2. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- SShenzhen Third People's Hospital